BIOSYNEX (EPA:ALBIO) | Finanzwire

Basculer en Français

8299	Companies
114942	Keywords
55348	Articles
62469	Press releases

Home
Companies
BIOSYNEX

BRIEF

published on 11/04/2024 at 18:05, 16 days 20 hours ago

BIOSYNEX SA: Declaration of Shares and Voting Rights

Voting Rights Actions Transparency Financial Markets BIOSYNEX
BRIEF

published on 10/23/2024 at 18:05, 28 days 20 hours ago

Chembio Diagnostics wins grant for new syphilis test

BIOSYNEX Chembio Diagnostics Congenital Syphilis Rapid Diagnosis Gates Foundation Grant
PRESS RELEASE

published on 10/23/2024 at 18:00, 28 days 20 hours ago

BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY
Chembio Diagnostics Inc., a subsidiary of BIOSYNEX, receives a grant to develop a rapid point-of-care diagnostic test for congenital syphilis supported by the Bill & Melinda Gates Foundation

Grant BIOSYNEX Congenital Syphilis Chembio Diagnostics Inc. Bill & Melinda Gates Foundation
BRIEF

published on 10/17/2024 at 18:05, 1 month 3 days ago

BIOSYNEX SA: 2024 Half-Year Results and Debt Restructuring

Revenue Growth Half-year Results Debt Restructuring Cost Rationalization American Expansions
BRIEF

published on 07/18/2024 at 18:05, 4 months 2 days ago

BIOSYNEX: Revenue for the first half of 2024 up 26%

Acquisitions Growth Turnover Export American Subsidiaries
BRIEF

published on 05/28/2024 at 17:50, 5 months 23 days ago

BIOSYNEX obtains its first CE markings according to the new IVDR regulations

In Vitro Diagnostics BIOSYNEX IVDR CE Marking Rapid Tests
BRIEF

published on 05/28/2024 at 17:50, 5 months 23 days ago

BIOSYNEX Obtains Its First CE Markings According to IVDR Regulations

BIOSYNEX IVDR CE Marking Rapid Tests Molecular Biology
BRIEF

published on 05/13/2024 at 20:22, 6 months 7 days ago

BIOSYNEX strengthens its governance and promotes new talents

Governance Chief Operating Officer ESG BIOSYNEX Health Diagnosis
BRIEF

published on 05/13/2024 at 18:05, 6 months 7 days ago

BIOSYNEX SA strengthens its governance with new appointments

Governance Appointments ESG Health BIOSYNEX
BRIEF

published on 05/03/2024 at 18:05, 6 months 17 days ago

BIOSYNEX announces its capital indicators for April 2024

Share Capital Voting Rights Financial Regulation BIOSYNEX Markets Financial Regulation

Accesswire

Published on 11/21/2024 at 14:15, 12 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 27 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 27 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 27 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 27 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 10 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 12 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 27 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 11 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 51 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 29 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 7 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 42 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 42 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE